article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. Brussels; 2020. EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2022.

article thumbnail

Roivant joins RNA splicing push with Eisai deal

pharmaphorum

The compound, called H3B-8800, is currently in phase 1 testing in the US and Europe in patients with myelodysplastic syndrome (MDS) who carry mutations in splicing factor 3B subunit 1 (SF3B1) by Eisai’s H3 Biomedicine subsidiary.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How to approach die plate adhesion during tableting

European Pharmaceutical Review

In most cases, formulation compounds represent a fixed starting point from which any changes can be implemented, whereas tableting process parameters as well as machine condition, can be managed and optimised to their best, combining the knowledge of the machine manufacturer with the experience of the pharmaceutical industry.

article thumbnail

Three strategies for managing loss of exclusivity successfully

pharmaphorum

Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively. AstraZeneca’s patent for its top-selling gastroesophageal reflux disease drug was due to expire in 2001. Simultaneous with the switch to NEXIUM, AstraZeneca grew its overall Gastroenterology franchise – by nearly 9% from 2001 to 2002.

article thumbnail

PROTAC development gains momentum, but clinical performance is poor

Pharmaceutical Technology

The first concept for a PROTAC was published in 2001, and recently these protein degraders have gained rapid momentum as a promising novel modality. This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active.

Dosage 59
article thumbnail

Brain Fog and Hashimoto’s

The Thyroid Pharmacist

Compounded medications : If NDT medications do not seem like a good fit for you, compounded T4/T3 products offer another alternative. Thyroid compounds are usually prepared in the same physiological ratio that is found in NDT products. I recommend 1-4 grams of fish oil per day, taken with a meal that contains quality fats.

article thumbnail

How Myo-inositol Can Improve Hashimoto’s Symptoms

The Thyroid Pharmacist

While the human body (via the liver and kidneys) can produce up to 4 g/day of inositol, it has been found that the overly processed, high glucose (and low fiber) Western diets that many people follow, only provide about 1 g/day of the compound. (7). Some people actually went into remission after starting the myo-inositol. Endokrynol Pol.